Booming biopharma
While headline-making deals were in relatively short supply during 2020, smaller deals including financing and more limited deals made it a record year for the biopharma sector, according to Clarivate, an analytical consultancy that claims to accelerate the pace of innovation. Read the C&I Leader article.